TECHNOLOGY TRANSFER OF STERILE PROPDUCTS - IIR

More documents

Recommendations

Info

Status of Pharmaceuticals and Biopharmaceuticals Pharma companies are starting to recognize that the cost of setting up and maintaining facilities - with a highly-skilled workforce to run them, the expertise necessary to continually update and improve them - does not always provide a good return on investment. Decision is then taken by Big Pharma Co to use CMOs. The market for contract manufacturing of prescription drugs for 2004 was estimated at $26.2bn, and is expected to rise to $43.9bn by end of 2009, a 10.8 per cent average annual growth rate. (From Business Communications Co.’s s soon to-be be-out report on Pharmaceutical Contract Manufacturing and Research, April 2005) . 4
Status of Pharmaceuticals and Biopharmaceuticals Drug development especially biomolecule-based based development is very expensive Exponential growth of Biotech companies in last 20 years. Unlike Pharma companies, Biotech companies many times lack expertise/infrastructure to bring drugs/biomolecule from discovery to development to commercialization. Emerging Biotech Co., hence, resort to outsourcing . 5
Page 1 and 2: TECHNOLOGY TRANSFER OF STERILE PROP
Page 3: Overview Current Status of Pharmac
Page 7 and 8: Late-Stage Biotech Development (Sou
Page 9 and 10: Types of Technology Transfer Origin
Page 11 and 12: Phase IV Typical Drug Development P
Page 13 and 14: Needs for Technology Transfer Reaso
Page 15 and 16: Phases In Evolution of Production S
Page 17 and 18: Schematic to Summarize Technology T
Page 19 and 20: Technology Transfer Process/Phases
Page 21 and 22: Technology Transfer Process 2. Tech
Page 23 and 24: Technology Transfer Process 2. Tech
Page 25 and 26: Technology Transfer Process 3. Vali
Page 27 and 28: Technology Transfer Process 3. Vali
Page 29 and 30: Technology Transfer Phases 3. Proje
Page 31 and 32: Schematic of Representative Bulk Pr
Page 33 and 34: Schematic of Representative Fill Fi
Page 35 and 36: Aseptic Manufacturing - Isolators V
Page 37 and 38: How to Conduct Technology Transfer
Page 39 and 40: Hypothetical Technology Transfer S
Page 41 and 42: Technology Transfer for Lyo Product
Page 55 and 56:
Technology Transfer for Lyo Product
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Hypothetical Technology Transfer (S
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Using CMO for Technology Transfer
Page 73 and 74:
Technology Transfer Essentials Pro
Page 75 and 76:
Technology Transfer Essentials Pro
Page 77 and 78:
Technology Transfer Success Factors
Page 79 and 80:
A Case Study Mixing Validation 79
Page 81 and 82:
Case Study - Mixing Validation •
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Thank you Questions 87
Page 89 and 90:
Strategy for Characterization of Ra
Page 91 and 92:
Air Classification Clean-Area Class
show all

TECHNOLOGY TRANSFER OF STERILE PROPDUCTS - IIR

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?